Omni Nashville | Broadway E & F
250 Rep. John Lewis Way S
Nashville, TN 37203
Family and primary care practitioners, including their care teams, advanced practice providers, and other healthcare professionals who treat patients with dyslipidemia.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this live material for a maximum of 1.5 AMA PRA Category 1 CreditsTM.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AAFP has reviewed New Approaches to Managing Dyslipidemia: Primary Prevention with a PCSK9 Inhibitor and deemed it acceptable for up to 1.50 Live AAFP Prescribed credits. Term of approval is from 10/23/2026 to 10/22/2027. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This session is approved for 1.5 Live AAFP Prescribed credits.
This activity has been supported by an independent educational grant from Amgen.
Omni Nashville | Broadway E & F
250 Rep. John Lewis Way S
Nashville, TN 37203
For all CE inquiries or special needs, please contact admin@academiccme.com.
Review clinical trial data on PCSK9i use for primary prevention and secondary prevention, while discussing strategies to optimize LDL-C therapies.
Discuss how to individualize PCSK9i therapy for patients who would benefit from primary prevention based on LDL-C levels, CV risk, comorbidities, and current guideline recommendations.
Identify referral strategies from primary care/family practice to cardiology to manage patients who experience suboptimal LDL-C control despite medication and lifestyle changes.
I. Welcome & Introductions – Alan Brown, MD
II. LDL-C: Lower for Longer is Better – Peter Toth, MD
III. Clinical Utility of PCSK9 Inhibitors in Primary Prevention – Alan Brown, MD
a. Guideline Recommendations, Comorbidities, LDL-C levels, Family History
b. Other, Emerging PCSK9 Inhibitors for Secondary Prevention
IV. Best Practices for Managing Side Effects from Lipid Lowering Agents – Ann Liebeskind, MD
V. Faculty Panel Discussion and Audience Q&A – All Faculty
I. Welcome & Introductions – Alan Brown, MD
II. LDL-C: Lower for Longer is Better – Peter Toth, MD
III. Clinical Utility of PCSK9 Inhibitors in Primary Prevention – Alan Brown, MD
a. Guideline Recommendations, Comorbidities, LDL-C levels, Family History
b. Other, Emerging PCSK9 Inhibitors for Secondary Prevention
IV. Best Practices for Managing Side Effects from Lipid Lowering Agents – Ann Liebeskind, MD
V. Faculty Panel Discussion and Audience Q&A – All Faculty